AXSM

Axsome Therapeut

• Seeking Alpha·05/14 18:50

  Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease

• TipRanks·05/11 11:20

  Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)

• TipRanks·05/08 18:46

  Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating

• Benzinga·05/08 16:02

  'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive

• PUBT·05/06 00:35

  Axsome COO Mark Jacobson disposes of common shares worth $1.08 million

• Dow Jones·05/05 15:44

  Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

• Benzinga·05/05 15:34

  Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $242

• Dow Jones·05/05 14:55

  Axsome Therapeutics Is Maintained at Outperform by RBC Capital

• Benzinga·05/05 14:45

  RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $302

• Dow Jones·05/05 13:44

  Axsome Therapeutics Price Target Raised to $255.00/Share From $225.00 by Wells Fargo

• Dow Jones·05/05 13:44

  Axsome Therapeutics Is Maintained at Overweight by Wells Fargo

• Benzinga·05/05 13:34

  Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $255

• Dow Jones·05/05 13:21

  Axsome Therapeutics Price Target Raised to $260.00/Share From $245.00 by Guggenheim

• Dow Jones·05/05 13:21

  Axsome Therapeutics Is Maintained at Buy by Guggenheim

• Benzinga·05/05 13:11

  Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $260